Dr. Matt Basel
A significant obstacle in cancer research is translating results from the lab bench to the hospital bed. Studies have shown that around 95% of drugs that succeed in preclinical trials fail to act the same way in clinical trials. One potential reason is the significant differences between the small animal models used to study cancers and human anatomy and physiology. We study methods to increase translatability of research by developing better models, e.g., through immunocompetent xenograft models and/or large animal models that more closely represent humans. Closely related, we also study highly targeted cancer therapy using nanotechnology and/or hyperthermia treatments to increase treatment efficacy while reducing side-effects.